Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Novartis, Ipsen, Pfizer, Camurus, Bayer, Eisai, Experior, Tarveda, Bayer

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are actively working on various pipeline drugs in the Gastroenteropancreatic Neuroendocrine Tumors therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market.

The report provides a detailed description of the Gastroenteropancreatic Neuroendocrine Tumors drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Gastroenteropancreatic Neuroendocrine Tumors Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Gastroenteropancreatic Neuroendocrine Tumors therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroenteropancreatic Neuroendocrine Tumors treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Gastroenteropancreatic Neuroendocrine Tumors drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Gastroenteropancreatic Neuroendocrine Tumors treatment market.

Learn More about the Clinical and Commercial Development Activities in the Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Domain @
https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Therapeutics Analysis
NETs arise throughout the body from cells of the diffuse endocrine system. More than half originate from endocrine cells of the gastrointestinal tract and the pancreas, thus being referred to as gastroenteropancreatic NETs (GEP NETs). The only treatment that offers a cure is surgery, however most patients are diagnosed with metastatic disease, and curative surgery is usually not an option.

Since the majority of patients are not candidate for curative surgery, they can be offered long-term systemic treatment, for both symptomatic relief and tumor growth suppression. Currently, the market of GEP-NETs is based on Surgery, approved therapies such as (Lutathera and Somatuline), surgery, off-label products such as (chemotherapy and cytotoxic agents), somatostatin analogue (SSAs), and targeted therapies Everolimus (Afinitor), Sunitinib maleate (Sutent) that are being contributing towards the market revenue of GEP-NETs.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Companies in the Therapeutics Market Include:
Some of the key companies in the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) market include Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.

Emerging and Marketed Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Therapies Covered in the Report Include:
• 177Lu-edotreotide: ITM Radiopharmaceutical
• CAM2029: Camurus AB
• RRx-001: EpicentRx
• CVM-1118 (TRX-818): TaiRx
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Gastroenteropancreatic Neuroendocrine Tumors Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Gastroenteropancreatic Neuroendocrine Tumors Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Table of Content
1. Report Introduction
2. Executive Summary
3. Gastroenteropancreatic Neuroendocrine Tumors Current Treatment Patterns
4. Gastroenteropancreatic Neuroendocrine Tumors - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Gastroenteropancreatic Neuroendocrine Tumors Late-Stage Products (Phase-III)
7. Gastroenteropancreatic Neuroendocrine Tumors Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gastroenteropancreatic Neuroendocrine Tumors Discontinued Products
13. Gastroenteropancreatic Neuroendocrine Tumors Product Profiles
14. Gastroenteropancreatic Neuroendocrine Tumors Companies
15. Gastroenteropancreatic Neuroendocrine Tumors Drugs
16. Dormant and Discontinued Products
17. Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs
18. Gastroenteropancreatic Neuroendocrine Tumors Future Perspectives
19. Gastroenteropancreatic Neuroendocrine Tumors Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.